Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.74 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1193579 | 0.92 | GLA (0.78) | GLAHTTKMT2APABPC1ATM | |
| SCHEMBL6226013 | 0.91 | GLA (0.75) | GLAHTTKMT2APABPC1ATM | |
| Bromide SCHEMBL1193716 | 0.84 | GLA (0.70) | GLAHTTKMT2APABPC1ATM | |
| Bromide SCHEMBL7061122 | 0.83 | GLA (0.65) | GLAHTTKMT2APABPC1ATM | |
| Bromide SCHEMBL1193999 | 0.83 | GLA (0.58) | GLAHTTKMT2APABPC1ATM | |
| Bromide SCHEMBL7514295 | 0.82 | ALDH1A1 (0.76) | GLAHTTKMT2APABPC1ATM | |
| SCHEMBL6225837 | 0.81 | GLA (0.56) | GLAHTTKMT2APABPC1ATM | |
| Bromide SCHEMBL1193574 | 0.80 | GLA (0.70) | GLAHTTKMT2APABPC1ATM | |
| Bromide SCHEMBL7053244 | 0.79 | GLA (0.70) | GLAHTTKMT2APABPC1ATM | |
| SCHEMBL6904837 | 0.78 | GLA (0.68) | GLAHTTKMT2APABPC1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030092744-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2003-05-15 | — | — | US | claimed |
| US-20010018524-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | TORRENT PHARMACEUTICALS LTD. (IN) | 2001-08-30 | — | — | US | claimed |
| US-6624178-B2 | Novel compounds of the pyridinium series useful for the management of diabetes and aging-related vascular complications, including kidney disease, nerve damage, atherosclerosis, retinopathy, dermatological disorders and | TORRENT PHARMACEUTICALS LTD. (IN) | 2003-09-23 | — | — | US | disclosed |
| US-20030092744-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2003-05-15 | — | — | US | disclosed |
| EP-1304101-A1 | Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications | Torrent Pharmaceuticals Ltd (IN) | 2003-04-23 | — | — | EP | disclosed |
| US-20030032660-A1 | Breaking preformed AGE | TORRENT PHARMACEUTICALS LTD. | 2003-02-13 | — | — | US | disclosed |
| US-6462057-B1 | SUCH AS 1-(2-ETHOXY-2-OXOETHYL)-3-(METHANESULFONYLHYDRAZINO-CARBONYL)PYRIDINIUM BROMIDE; KIDNEY DISEASE, NERVE DAMAGE, ATHEROSCLEROSIS, RETINOPATHY, DERMATOLOGICAL DISORDERS AND DISCOLORATION OF TEETH | TORRENT PHARMACEUTICALS, LTD. (IN) | 2002-10-08 | — | — | US | disclosed |
| US-20020103228-A1 | Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications | TORRENT PHARMACEUTICALS LTD. | 2002-08-01 | — | — | US | disclosed |
| US-20010018524-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | TORRENT PHARMACEUTICALS LTD. (IN) | 2001-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018524-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | AGER, GLA, RBP1 | GLA 2/4885HTT 4615/4885KMT2A 4629/4885 |
| US-20030092744-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | AGER, REN, RBP4 | GLA 5/4885HTT 4568/4885KMT2A 4408/4885 |
| US-20030032660-A1 | Breaking preformed AGE | AGER, GPX1, RBP1 | GLA 22/4885HTT 4717/4885KMT2A 4457/4885 |
| US-20020103228-A1 | Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications | PNPO, PRDX5, PLPBP | GLA 253/4885HTT 3647/4885KMT2A 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.